Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells

Blood

Volumn 88, Issue 7, 1996, Pages 2450-2457

  Molldrem, Jeffrey ^a   Dermime, Said ^b   Parker, Kenneth ^b   Jiang, Yin Zheng ^b   Mavroudis, Dimitrios ^b   Hensel, Nancy ^b   Fukushima, Paula ^b   Barrett, A John ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; PROTEINASE;

ANTIGEN RECOGNITION; ARTICLE; CELL DIFFERENTIATION; CHROMOSOME 19; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG RECEPTOR BINDING; ENZYME SPECIFICITY; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

EID: 0029838112     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.7.2450.bloodjournal8872450     Document Type: Article

References (40)

1. Sosman JA, Oettel KR, Smith SD, Hank JA, Fisch P, Sondel PM: Specific recognition of human leukemic cells by allogeneic T cells. II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated non-leukemic cells. Blood 75:2005, 1990
2. van Lochem E, de Gast B, Goulmy E: In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 10:181, 1992
3. Falkenburg JHF, Faber LM, van den Elshout M, van Luxemburg-Heijs SAP, Hooftman-den Otter A, Smit WM, Voogt PJ, Willemze R: Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation. J Immunother 14:305, 1993
4. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O'Reilly RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 4:1261, 1995
5. van der Harst D, Goulmy E, Falkenburg JHF, Kooij-Winkelaar YMC, van Luxemburg-Heijs SAP, Goselink HM, Brand A: Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 4:1060, 1994
6. Pion S, Fontaine P, Baron C, Gyger M, Perreault C: Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy. J Clin Invest 95:1561, 1995
7. Faber LM, van der Hoeven J, Goulmy E, Hooftman-den Otter AL, van Luxemburg-Heijs SAP, Willemze R, Falkenburg JHF: Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest 96:877, 1995
8. Truitt RL, Johnson BD: Principles of graft-versus-leukemia reactivity. Biol Blood Marrow Transplant 1:61, 1995
9. BCR-ABL protein. Proc Natl Acad Sci USA 89:1468, 1992
10. Dermime S, Molldrem J, Parker KC, Jiang YZ, Mavroudis D, Hensel N, Couriel D, Mahoney M, Coligan JE, Barrett AJ: Human CD8+ T lymphocytes recognize the fusion region of bcr/abl hybrid protein present in chronic myelogenous leukemia. Blood 86:158a, 1995 (abstr, suppl 1)
11. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yan SY, Sette A, Scheinberg DA: Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87:3587, 1996
12. Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG. Parmiani G: Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RARα present in acute promyelocytic leukemia cells. Blood 81:1369, 1993
13. Skipper J, Stauss HS: Identification of two cytotoxic T lymphocyte-recognized epitopes in the ras protein. J Exp Med 117:1493, 1993
14. Townsend A, Ohlen C, Rogers M, Edwards J, Mukherjee S, Bastin J: Source of unique tumor antigens. Nature 371:662, 1994
15. Houghton AN: Cancer antigens: Immune recognition of self and altered self. J Exp Med 180:1, 1994
16. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92:432, 1995
17. 1- cells from the same patient. Blood 83:3390, 1994
18. Dermime S, Bertazzoli C, Marchesi E, Ravagnani F, Blaser K, Corneo GM, Pogliani E, Parmiani G, Gambacorti-Passerini C: Lack of T-cell-mediated recognition of the fusion region of the pml/RARα hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Clin Cancer Res 2:593, 1996
19. Boon T, Cerottini JC, Van den Eynd B, van der Bruggen P, Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337, 1994
20. Rao NV, Wehner NG, Marshall BC, Gray WR, Gray BH, Hoidal JR: Characterization of proteinase-3 (PR-3), a neutrophil serine pcoteinase. J Biol Chem 266:9540, 1991
21. Sturrock AB, Franklin KF, Rao G, Marshall BC, Rebentisch MB, Lemons RS, Hoidal JR: Structure, chromosomal assignment, and expression of the gene for proteinase 3. J Biol Chem 267:21193, 1992
22. Dengler R, Münstermann U, Al-Batran S, Hausner I, Faderl S, Nerl C, Emmerich B: Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br J Haematol 89:250, 1995
23. Bories D, Raynal MC, Solomon DH, Darzynkiewicz Z, Cayre YE: Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 59:959, 1989
24. Goldschmeding R, van der Schoot CE, ten Bokkel Huinink D, Hack CE, van den Ende ME, Kallenberg CGM, von dem Borne AEG: Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest 84:1577, 1989
25. Brouwer E, Stegeman CA, Huitema MG, Limburg PC, Kallenberg CGM: T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 98:448, 1994
26. Ballieux BEPB, van der Burg SH, Hagen EC, van der Woude FJ, Melief CJM, Daha MR: Cell-mediated autoimmunity in patients with Wegener's granulomatosis (WG). Clin Exp Immunol 100:186, 1995
27. Rammensee HG, Friede T, Stevanovic S: MHC ligands and peptide motifs: First listing. Immunogenetics 41:178, 1995
28. Zweerink HJ, Gammon MC, Utz R, Sauma SY, Harrer T, Hawkins JC, Johnson RP, Sirotina A, Hermes JD, Walker BD, Biddison WE: Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J Immunol 150:1763, 1993
29. Jiang YZ, Couriel D, Mavroudis DA, Lewalle P, Malkovska V, Hensel NF, Dermime S, Molldrem J, Barrett AJ: Interaction of natural killer cells with MHC class II: Reversal of HLA-DR1-mediated protection of K562 transfection from natural killer cells-mediated cytolysis by brefeldin-A. Immunology 87:481, 1996
30. 2 -microglobulin dissociation rate is an accurate measure of the stability of MHC class I heterotrimers and depends on which peptide is bound. J Immunol 149:1896, 1992
31. Jiang YZ, Mavroudis D, Dermime S, Hensel N, Couriel D, Molldrem J, Barrett AJ: Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol 93:606, 1996
32. Levitsky V, Zhang QJ, Levitskaya J, Masucci MG: The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4. J Exp Med 183:915, 1996
33. van der Burg SH, Visseren MJW, Brandt RMP, Kast WM, Melief CJM: Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 156:3308, 1996
34. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458, 1994
35. Nanda NK, Sercarz EE: Induction of anti-self-immunity to cure cancer. Cell 82:13, 1995
36. Chen W, Chatta K, Rubin W, Liggitt DH, Kusunoki Y, Martin P, Cheever MA: Polymorphic segments of CD45 can serve as targets for GVHD and GVL responses. Blood 86:158a, 1995 (abstr, suppl 1)
37. Malkovska V, Cigel F, Sondel P, Parker K: Synthetic peptides derived from the CD19 protein bind to the class I HLA-A2.1. Blood 86:157a, 1995 (abstr, suppl 1)
38. Dupuis M, Kundu SK, Merigan TC: Characterization of HLA-A*0201-restricted cytotoxic T cell epitopes in conserved regions of the HIV type 1 gp160 protein. J Immunol 155:2232, 1995
39. Matulonis UA, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, Griffin JD: Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85:2507, 1995
40. Bonini C, Verzeletti S, Servida P, Rossini S, Traversari C, Ferrari G, Nobili N, Mavillio F: Transfer of the HSV-TK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity after allo-BMT. Blood 84:427, 1994